Gain Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · · | |||||||||||||||||
| · Shares · Amounts · Capital · Income (Loss) · Deficit · Total | |||||||||||||||||
| Balance as of December 31, 2024 | | 27,132,588 | | $2,713 | | $88,779,318 | | $(247,549) | | $(81,194,908) | | $7,339,574 | |||||
| Stock-based compensation (Note 15) | | 63,859 | | 6 | | 423,139 | | — | | — | | 423,145 | |||||
| Exercise of warrants (Note 14) | | 454,893 | | | 47 | | | — | | | — | | | — | | | 47 |
| Changes in defined benefit pension plan obligation (Note 11) | | — | | — | | — | | 4,826 | | — | | 4,826 | |||||
| Foreign currency translation | | — | | — | | — | | 122,858 | | — | | 122,858 | |||||
| Issuance of shares in at-the-market ("ATM") offering (Note 14) | | 1,094,701 | | | 109 | | | 2,419,210 | | | — | | | — | | | 2,419,319 |
| Net loss | | — | | | — | | | — | | | — | | | (4,530,058) | | | (4,530,058) |
| Balance as of March 31, 2025 | | 28,746,041 | | $2,875 | | $91,621,667 | | $(119,865) | | $(85,724,966) | | $5,779,711 | |||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of December 31, 2023 | | 16,206,680 | | $1,621 | | $73,113,079 | | $247,241 | | $(60,783,717) | | $12,578,224 | |||||
| Stock-based compensation (Note 15) | | 31,125 | | 3 | | 145,470 | | — | | — | | 145,473 | |||||
| Exercise of stock options (Note 14) | | 15,983 | | | 2 | | | 57,709 | | | — | | | — | | | 57,711 |
| Exercise of warrants (Note 14) | | 1,787,443 | | | 179 | | | 100,046 | | | — | | | — | | | 100,225 |
| Defined benefit pension plan adjustments (Note 11) | | — | | — | | — | | 1,086 | | — | | 1,086 | |||||
| Foreign currency translation | | — | | — | | — | | (230,792) | | — | | (230,792) | |||||
| Net unrealized gain on available-for-sale securities (Note 5) | | — | | | — | | | — | | | 4,328 | | | — | | | 4,328 |
| Net loss | | — | | | — | | | — | | | — | | | (4,014,194) | | | (4,014,194) |
| Balance as of March 31, 2024 | | 18,041,231 | | $1,805 | | $73,416,304 | | $21,863 | | $(64,797,911) | | $8,642,061 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.